NIH plans to support research using data from expanded access protocols that provide investigational treatments to people with ALS; applications are not yet being solicited.
This grant will fund research using data from expanded access to investigational drugs for ALS patients who are ineligible for clinical trials, aiming to improve prevention, diagnosis, or treatment of ALS.
Funds research to develop medical products for treating or curing ALS and other rare neurodegenerative diseases in adults and children.
The Hoffman ALS Clinical Trial Awards Program supports researchers conducting biomarker-driven early trials of ALS therapies and imaging tracers to advance treatment development and care.
Supports investigator-initiated clinical trials for neurological disorders, from early exploratory studies to Phase 3 confirmatory and comparative effectiveness trials.
The Lawrence and Isabel Barnett Drug Development Program supports academic and industry investigators conducting preclinical studies of new or repurposed ALS therapies to advance them toward clinical testing.